Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix's Q4 Revenues Slide 6.5 Percent as Profit Plummets 72 Percent

NEW YORK (GenomeWeb News) —Affymetrix today said fourth-quarter revenues decreased 6.5 percent as R&D spending remained flat and profit plummeted 72 percent.
 
Total receipts for the three months ended Dec. 31, 2006, decreased to $104.2 million from $111.4 million year over year.
 
Product and product-related revenue decreased 9.5 percent to $95 million; royalties and "other" revenue increased 115 percent to $6.6 million; and receipts from Perlegen slid 5.5 percent to $2.6 million.
 
R&D spending was flat at $19.6 million.
 
The company said profit declined to $8.7 million from $30.6 million in the year-ago period.
 
Affy said it had around $119 million in cash and equivalents and $118 million in short-term investments as of Dec. 31.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.